Bradford D. Dahms - 12 Feb 2026 Form 4 Insider Report for Jade Biosciences, Inc. (JBIO)

Role: Chief Financial Officer
Signature: /s/ Elizabeth Balta, as attorney-in-fact for Bradford D. Dahms
Issuer symbol: JBIO
Transactions as of: 12 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 13 Feb 2026, 20:00:45 UTC
Previous filing: 14 Jul 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Dahms Bradford D.	Chief Financial Officer	C/O JADE BIOSCIENCES, INC., 221 CRESCENT ST., BLDG. 23, STE. 105, WALTHAM	/s/ Elizabeth Balta, as attorney-in-fact for Bradford D. Dahms	13 Feb 2026	0001787307

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	JBIO	Common Stock	Award	$0	+37,813		$0.000000	37,813	12 Feb 2026	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	JBIO	Stock Option (Right to Buy)	Award	$0	+226,875		$0.000000	226,875	12 Feb 2026	Common Stock	226,875	$14.81	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs"). 1/4 of the total number of RSUs granted shall vest on each of the first four anniversaries of February 15, 2026, the vesting commencement date, subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
F2	This option represents a right to purchase shares of the Issuer's common stock, one quarter of which will vest on February 15, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.